INOVIO PHARMACEUTICALS INC (INO) Stock News
NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD
INO Latest News, Press Relases and Analysis
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
What's Going On With Inovio Pharmaceuticals (INO) Stock?
Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing
Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses.
INOVIO Announces Pricing of $30 Million Public Offering
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
INOVIO Announces Proposed Public Offering
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
INOVIO Reports Inducement Grant Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
INO earnings call for the period ending September 30, 2024.
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an...
INOVIO to Present at Upcoming Scientific Conferences
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Reports Inducement Grants Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Present at Upcoming Scientific Conferences
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to...
INOVIO to Present at Upcoming Scientific Conference
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inovio Pharmaceuticals (NASDAQ:INO) just reported results for the second quarte...
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
INO earnings call for the period ending June 30, 2024.
INO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
INO stock results show that Inovio Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...